Computer Science · Artificial Intelligence
Escalating Dose of Mitoxantrone With High-Dose Cyclophosphamide, Carmustine, and Etoposide in Patients With Refractory Lymphoma Undergoing
Autologous Bone, Marrow Transplantation, Michel Attal Pierre Canal, Catherine Payen, Jacques Pris, Guy Laurent
See on the mapAbstract
Purpose: We conducted a dose-finding study of mi-toxantrone (MITO) in combination with high-dose cyclo-phosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT). The objectives were to determine the following: (1) the maximum-tolerated dose of MITO, (2) the extramedullary toxicity of this regi-men, (3) its antitumor activity, and (4) the pharmacoki-netic characteristics of MITO at each dose level. Patients and Methods: Escalating doses of MITO (15 to 90 mg/m', single bolus infusion on day-8) followed by CBV were administered to 20 patients (mean age, 38.5 years) with refractory lymphoma. MITO concentra-tions were determined by high-performance liquid chro-matography (HPLC).